ORIGINAL COMMUNICATION

Ocular phenotype and electroretinogram abnormalities in Lafora disease and correlation with disease stage

Alessandro Orsini1 · Daniele Ferrari2 · Antonella Riva3,4 · Andrea Santangelo1 · Angelo Macrì2 · Elena Freri5 · Laura Canafoglia6 · Alfredo D’Aniello7 · Giancarlo Di Gennaro7 · Gabriele Massimetti8 · Carlo Minetti3 · Federico Zara3 · Roberto Michelucci9 · Anupreet Tumber10 · Ajoy Vincent10 · Berge Arakel Minassian11 · Pasquale Striano3,4

Received: 20 November 2021 / Revised: 12 January 2022 / Accepted: 13 January 2022 / Published online: 20 February 2022
© The Author(s) 2022

Abstract

Background Lafora disease (LD) is a neurodegenerative disorder featuring action and stimulus-sensitive myoclonus, epilepsy, and cognitive deterioration. Mutations in the \(EPM2A/EPM2B\) genes classically prove causative for the disease in most cases. Since full-field electroretinogram (ffERG) may reveal early-stage changes in a wide spectrum of diseases, we aimed to evaluate retinal cones and rods dysfunction in a cohort of Italian LD patients.

Methods Patients with genetically confirmed LD were recruited and subjected to ffERG analysis following the International Society for Clinical Electrophysiology of Vision (ISCEV) protocol.

Results Six patients aged between 13 and 26 years (mean 19.5 years) were included. The mean age at disease onset was 12.5 years with a mean disease duration of 7 years. The ffERG analysis revealed a global mild to severe generalized cones dysfunction in all patients. Linear correlation was identified between disease stage and the degree of cones and rods dysfunction, as well as between the type of mutation and the cones and rods dysfunction.

Conclusions This study brings further evidence of early retinal alterations in LD patients. The cones and rods dysfunction grade is related to disease duration. The ffERG is an important tool to determine the disease stage, allowing to evaluate either natural or treatment-related disease progression in a minimally invasive way.

Keywords FFERG · Lafora disease · Neurodegeneration · Progressive myoclonus · Retinal alterations
Introduction

Lafora disease (LD) is a progressive myoclonus epilepsy characterized by the abrupt onset of action and stimulus-sensitive myoclonus in otherwise neurologically normal adolescents [1, 2]. Initial symptoms rapidly turn into progressive dementia, refractory status epilepticus, psychosis, cerebellar ataxia, dysarthria, mutism, and respiratory failure, eventually leading to a severe burden of disability or death within 10 years [1, 3, 4].

LD is primarily caused by mutations of two genes: EPM2A and EPM2B (NHLRC1). Both genes are located on chromosome 6 at q24.3 and p22.3, respectively. The EPM2A gene encodes the laforin dual-specificity phosphatase, while the EPM2B encodes the malin ubiquitin E3 ligase. These proteins are involved in glycoprotein metabolism, thus causing the deposition of fibrillar polysaccharides composed of poorly branched glucose polymers, which are called Lafora bodies (LBs). Neuronal LBs mainly localize in dendrites but not in axons, possibly explaining the cortical hyperexcitability reported in LD [4, 5]. A slower disease course with delayed age at death has been reported in most subjects with EPM2B mutations [6–8]. Particularly, patients harbouring the p.(D146N) EPM2B mutation invariably show atypical milder LD, with delayed disease onset and prolonged disease course [9–11]. Nowadays, next-generation sequencing technologies have shortened the time needed for the diagnosis of several neurological disorders, including LD [12]. Nevertheless, predicting the prognosis and the evolution of LD remains challenging in most patients.

Full-field electroretinogram (ffERG) is a minimally invasive ophthalmological test measuring the electrical activity generated by neural cells in the retina in response to a light stimulus. ffERG can provide diagnostic and prognostic information on a variety of acquired and congenital retinal disorders [13] including retinitis pigmentosa [14], Stargardt disease [15], and Mucopolysaccharidoses [16]. Furthermore, ffERG has been suggested as a useful tool to assess potential retinal toxicity of various treatments [17, 18]. Since recent studies have identified useful ophthalmological biomarkers and displayed early ffERG alterations in LD patients [19], we aimed to evaluate retinal cones and rods dysfunction in a cohort of Italian LD patients.

Methods

Patients with genetically confirmed LD were recruited for the study. Clinical data including age at disease onset, seizure frequency, and concomitant pharmacological treatments were collected through a standardized questionnaire. The Magaudda Simplified Myoclonus Rate Scale and a simplified disability scale were used to assess myoclonus severity and walk capability as previously described [9].

For the ophthalmological evaluation, the visual acuity was first measured with the ETDRS visual acuity charts. Red–green color vision was assessed using Ishihara’s test. Then, ffERG was performed following the International Society for Clinical Electrophysiology of Vision (ISCEV) standard protocol, aiming at evaluating the rods and cones electrophysiological responses. After twenty minutes of dark adaptation (DA), patients underwent scotopic ffERG, using a 0.01 cd s/m² flash, which evokes a positive b-wave and represents rod bipolar cells’ activity. The second stimulation was a DA 3.0 cd s/m² flash, eliciting a negative a-wave arising from rod photoreceptors hyperpolarization, which is followed by the positive b-wave reflecting rod bipolar cell depolarization. Then, the DA oscillatory potentials test was performed to evoke responses from amacrine cells, and, after completion, patients were light-adapted (LA) for 10 min through a background luminance of 30 cd/m². Lastly, the cones system was tested using a 3.0 cd s/m² flash stimulus at two different frequencies: 2 Hz photopic ERG and 30 Hz flicker ERG. The 2 Hz frequency aroused an a-wave followed by a b-wave; in this case, the a-wave is driven by cone photoreceptors and cones Off-bipolar cells, whereas the b-wave by cone On- and Off-bipolar cells. The 30 Hz frequency flicker response reflects post-receptoral responses of cones On- and Off-pathways. Finally, spectral-domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF) were performed.

Statistical analysis

We investigated the relationship between disease stage and rods and cones dysfunction by scattergrams and computed Pearson’s correlation coefficients r/regression coefficients b. Independent sample t tests compared the mean level of rods and cones dysfunction observed in the two groups of LD patients (EPM2A vs EPM2B mutated).

Results

Six patients (3 EPM2A, 3 EPM2B) were investigated. Age at evaluation ranged from 13 to 26 years (mean 19.5 years), while age at disease onset ranged from 11 to 16 years (mean 12.5 years) with a mean disease duration of 7 years (range 2–13 years). The myoclonus severity scored between 0 and 4 points (mean, 2.50 points) and the disease stage ranged from 0 to 4 points (mean 2.67 points) (Table 1). The retinal anatomy, FAF, SD-OCT, visual acuity, and color vision tests were unremarkable.
Table 1  Demographics, clinical and genetic data, and ffERG results of LD patients

| PtID | Gender | Age at last evaluation (years) | Age at onset (years) | Disease duration (years) | ffERG results | Amplitude deviation (SD) RE/LE | Disease stage at the examination | Genetic findings |
|------|--------|-------------------------------|---------------------|-------------------------|---------------|--------------------------------|--------------------------------|-----------------|
| P1   | M      | 18                            | 13                 | 5                       |               | ERG flicker: − 7.0/− 7.1; PHOT: − 10/− 8.3; SCOT: − 9.4/− 9.4 | 3                              | EPM2B: c.436G > A (p.Asp146Asn); c.838G > A (p.Glu280Lys) |
| P2   | F      | 13                            | 11                 | 2                       |               | ERG flicker: − 2.8/− 3; PHOT: − 3.3/− 3.5; SCOT: − 4/− 3.9 | 0                              | EPM2A: c.323G > T (p.Arg108Leu) |
| P3   | F      | 20                            | 11                 | 9                       |               | ERG flicker: − 5.8/− 6.9; PHOT: − 6.5/− 5.6; SCOT: − 4.8/− 4.3 | 3                              | EPM2A: c.323G > T (p.Arg108Leu) |
| P4   | F      | 26                            | 13                 | 13                      |               | ERG flicker: − 3.9/− 2.9; PHOT: − 10/− 8.2; SCOT: − 7.4/− 9.5 | 4                              | EPM2A: c.243_246del (p.Asp82ArgfsTer7) |
| P5   | F      | 20                            | 11                 | 9                       |               | ERG flicker: − 4.6/− 2.8; PHOT: − 4.5/− 5.6; SCOT: − 3.6/− 3.9 | 4                              | EPM2B: c.205C > G (p.Pro69Ala); c.826_829dup (p.Ala277AspfsTer23) |
| P6   | M      | 20                            | 16                 | 4                       |               | ERG flicker: − 5.4/− 5.9; PHOT: − 7.6/− 9.4; SCOT: − 8.1/− 7.7 | 2                              | EPM2B: c.468_469del (p.Pro69Ala); c.205C > G |

F female, ffERG full-field electroretinogram, FU follow-up, LE left eye, M male, PHOT photopic, Pt patient, RE right eye, SCOT scotopic, y years

in all individuals. No patients showed retinitis pigmentosa, excluding retinal pigment epithelial atrophy, or any significant structural abnormality of the photoreceptor outer segments in the central retina (50°). We did not detect structural alterations in the macula on SD-OCT. The ffERG analysis revealed a generalized mild to severe cones dysfunction in all patients, traces are reported in Fig. 1, whereas raw values are displayed in Table 2. Specifically, mild cones dysfunction was detected in one patient (#P2; amplitude deviation RE/LE: − 3.3/− 3.5), whereas a moderate dysfunction was found in patients #P3 and #P5 (mean amplitude deviation RE/LE: − 5.5/− 5.6), and severe cones dysfunction was noted in three patients #P1, #P4, and #P6 (mean amplitude deviation: − 9.2/− 8.6) (Table 1). A positive correlation coefficient ($r = 0.597$) between the LD stage and the degree of cones and rods dysfunction at the ffERG analysis was observed; the linear relationship is well represented by the regression line ($y = 1.47 + 0.32x$) (Fig. 2). Table 3 shows the Pearson correlation coefficients. For full-field ERG, we found a stronger linear correlation ($r = 0.597$, p value 0.211) between cones and rods dysfunction and the disease stage. We found a moderate/strong correlation for photopic (PHOT) LE ($r = 0.525$, p value 0.285) and ERG-LE ($r = 0.407$, p value 0.211), whereas a weak correlation has been observed for scotopic (SCOT) LE ($r = 0.184$, p value 0.727). However, $t$ test analysis for the EPM2A and EPM2B subgroups displayed no significant difference for ffERG ($2.67 ± 0.58$ vs. $2.00 ± 1.0$, p value 0.374), (Fig. 3) ERG-LE ($− 5.67 ± 1.22$ vs. $− 4.17 ± 1.52$, p value 0.253), PHOT-LE ($− 7.37 ± 2.76$ vs. $− 6.60 ± 3.35$, p value 0.775) and SCOT-LE ($− 7.03 ± 3.04$ vs. $− 5.40 ± 1.78$, p value 0.467), as shown in Table 4.

**Discussion**

Both the retina and optic nerve share their embryological origin and vasculature with the brain, and the inner blood–retinal barrier and aqueous humour recall the blood–brain barrier and cerebrospinal fluid. For this reason, ophthalmological tests have been employed as a non- or minimally invasive tool for evaluating neural integrity in a wide range of neurological conditions which cause impairment in visual functions. Thus, an altered contrast sensitivity could be assessed in the early stages of Parkinson’s or Huntington’s diseases [20]. Moreover, OCT has recently been employed to identify specific markers of prediction, diagnosis, and progression of neurological conditions such as GLUT 1-deficiency.

Given that visual disturbances of LD patients are hardly evaluable through common ophthalmological evaluation, particularly in the early stages of the disease, to identify a safe, non-invasive, and rapid biological marker of LD
Fig. 1 Full-field electroretinogram (fERG) traces from patients and controls. Dark-adapted (DA) and light-adapted (LA) testing delineate rods and cones system function. Stimulus names include adaptive state of the eye (DA or LA) followed by stimulus intensity in cd.s.m-2. Under DA conditions two different intensity stimulus were used: 0.01, 3.0 cd/s/m². Under LA conditions two different stimuli were used at 3.0 cd/s/m²: 2Hz and 30 Hz (Flicker).
we examined the retinal anatomy, FAF, SD-OCT, visual acuity, and colour vision of six patients with a genetically confirmed diagnosis of LD. During the ophthalmological evaluation, the retinal anatomy was unremarkable. FAF, SD-OCT (retinal lamination at the macula), visual acuity, and color vision was normal. In our cohort, we were able to perform the flashing light, because the patients had a mean disease stage of 2.67 and did minimally react to the flashing stimulus being sufficiently collaborative to perform an accurate ERG study. In a previous study by Korczyn and colleagues [21], it was reported a gradual improvement of the b-wave over time (from 30 s to 14 min); however, these b-waves still did not reach normal

### Table 2
**fERG raw values observed in our cohort**

| Patient | Eye | DA 0.01 B-wave | DA 3.0 A-wave | DA 3.0 B-wave | Ficker Peak | LA 3.0 A-wave | LA 3.0 B-wave |
|---------|-----|----------------|---------------|---------------|-------------|---------------|---------------|
|         |     | ms µV          | ms µV         | ms µV         | ms µV       | ms µV        | ms µV         |
| P2      | L   | 58.50 40.69    | 23.00 − 17.54 | 37.50 61.62   | 46.00 54.44 | 16.00 − 11.28 | 32.00 48.32  |
| P3      | L   | 67.00 36.37    | 18.00 − 12.37 | 41.50 25.96   | 45.50 26.15 | 16.50 − 4.54 | 34.00 19.49  |
| P1      | L   | 59.00 7.66     | 17.50 − 7.56  | 32.00 18.07   | 50.50 24.58 | 16.50 − 5.35 | 35.00 5.81   |
| P4      | L   | 84.00 13.38    | 28.50 − 15.91 | 45.50 36.23   | 54.00 21.02 | 14.00 − 2.10 | 36.50 6.84   |
| P5      | L   | 74.50 26.14    | 17.00 − 31.86 | 40.00 45.77   | 46.00 63.83 | 12.50 − 12.55| 33.00 34.02  |
| P6      | L   | 59.00 13.47    | 17.00 − 15.04 | 35.00 26.33   | 45.50 18.08 | 13.50 − 3.78 | 33.50 13.90  |
| Control | L   | 66.50 80.38    | 24.50 − 131.55| 41.50 197.15  | 44.00 193.69| 16.50 − 32.83| 32.50 199.48|

### Table 3
Pearson’s correlation coefficients describing the relationship between cones and rods dysfunction and the disease stage

|          | r    | p   |
|----------|------|-----|
| Full-field ERG | 0.597 | 0.211 |
| ERG-LE     | −0.407| 0.424|
| PHOT-LE    | −0.525| 0.285|
| SCOT-LE    | −0.184| 0.727|

**ERG** electroretinogram, **LE** left eye, **PHOT** photopic, **RE** right eye, **SCOT** scotopic

### Table 4
T tests results in the comparison between EPM2A and EPM2B groups on the type of mutation and the cones and rods dysfunction

|          | EPM2A group (mean ± SD) | EPM2B group (mean ± SD) | p   |
|----------|-------------------------|-------------------------|-----|
| Full-field ERG | 2.67 ± 0.58          | 2.00 ± 1.0              | 0.374|
| ERG-LE     | −5.67 ± 1.22           | −4.17 ± 1.52            | 0.253|
| PHOT-LE    | −7.37 ± 2.76           | −6.60 ± 3.35            | 0.775|
| SCOT-LE    | −7.03 ± 3.04           | −5.40 ± 1.78            | 0.467|

**ERG** electroretinogram, **LE** left eye, **PHOT** photopic, **RE** right eye, **SCOT** scotopic

---

*Fig. 2* Positive linear correlation observed between LD stage and the grade of cones’ and rods’ dysfunction at the ERG analysis

*Fig. 3* Mean full-field ERG values in the EPM2A and EPM2B mutations subgroups
amplitudes. In our study, we performed standard ERGs following 20-min dark adaptation and observed reduction in both a- and b-wave amplitudes compared to controls who have ERG done identically. Furthermore, the intensities of light used for stimulation is different between the two studies.

The cones dysfunction was mainly in the moderate–severe stages (5/6 cases). Bipolar cell dysfunction observed at the ffERG may thus reflect the histological bipolar cells’ atrophy described in LD. Noteworthy, we identified a positive linear correlation between the disease stage and either the severity of cones dysfunction or the decreased rods photoreceptors a-wave amplitude function in the left eye (Figs. 2, 4, 5). Moreover, Fig. 1, shows how all ffERG traces are altered and reduced in amplitude in our patients as compared to healthy controls.

We were not able to perform Retinal Nerve Fiber Layer (RNFL) thickness measurements in patients due to invalidating psychomotor status of patients, but a recent case series showed reduced retinal thickness in two patients [22] and due to the small sample size, we failed to identify a statistical significance for the rod photoreceptors’ a-wave amplitude function in the right eye. Nevertheless, we showed that EPM2A patients display a more severe dysfunction of both cones and rods photoreceptors (Figs. 1, 3) and show global cones and rods photoreceptors’ dysfunction in all the patients, confirming the preliminary results by Vincent et al. [19]. Although, these findings need to be evaluated more thoroughly in a large series of patients to ascertain whether they are consistent and, if yes if they progress longitudinally.

In summary, we bring further evidence of early retinal alterations in LD patients, regardless of the disease stage but being the dysfunction grade possibly related to disease duration. Hence, ffERG sets as an important tool to evaluate stages of LD, allowing to evaluate either natural or treatment-related disease progression in a minimally invasive way and to early intervene with gene-based therapies as soon as they will be affordable for patients.
Acknowledgements  This work was developed within the framework of the DINOGMI Department of Excellence of MIUR 2018-2022 (legge 232 del 2016).

Declarations

Conflicts of interest  P.S has served on a scientific advisory board for the Italian Agency of the Drug (AIFA); has received honoraria from GW pharma, Kolfarma s.r.l and Eisai Inc.; and has received research support from the Italian Ministry of Health and Fondazione San Paolo. G. DiG. has participated in advisory boards and pharmaceutical industry-sponsored symposia for Arvelle, BIAL, Eisai, LivaNova, Lusofarmaco and UCB Pharma. A.D’A. has participated in pharmaceutical industry-sponsored clinicaltrials for UCB Pharma and symposia for Eisai, Lusofarmaco and UCB Pharma. A.R has received honoraria from Kolfarma s.r.l and Proveca Pharma Ltd. All the authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or conflict with the subject matter or materials discussed in this manuscript apart from those disclosed.

Fig. 5 Graph showing the linear correlation between LD stage and the grade of photoceptors’ dysfunction for each eye for the different analyses. LE left eye, RE right eye, ERG electroretinogram, PHOT photopic, SCOT scotopic
Ethical standards  This study has been approved by the institutional review boards and has, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References
1. Orsini A, Valetto A, Bertini V et al (2019) The best evidence for progressive myoclonic epilepsy: a pathway to precision therapy. Seizure 71:247–257
2. Minassian BA, Striano P, Avanzini G (2016) Progressive myoclonus epilepsy: the gene-empowered era. Epileptic Disord Int Epilepsy J Videotape 18(S2):1–2
3. Striano P, Zara F, Turnbull J et al (2008) Typical progression of myoclonic epilepsy of the Lafora type: a case report. Nat Clin Pract Neurol 4(2):106–111
4. Minassian BA (2001) Lafora’s disease: towards a clinical, pathologic, and molecular synthesis. Pediatr Neurol 25(1):21–29
5. Cavanagh JB (1999) Corpora-amylacea and the family of polyglucosan diseases. Brain Res Brain Res Rev 29(2–3):265–295
6. Chan EM, Bulman DE, Paterson AD et al (2003) Genetic mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22. J Med Genet 40(9):671–675
7. Gómez-Abad C, Gómez-Garre P, Gutiérrez-Delicado E et al (2005) Lafora disease due to EPM2B mutations. Neurology 64(6):982
8. Riva A, Orsini A, Scala M et al (2021) Italian cohort of Lafora disease: clinical features, disease evolution, and genotype-phenotype correlations. J Neurol Sci 424:117409
9. Franceschetti S, Gambardella A, Canafoglia L et al (2006) Clinical and genetic findings in 26 Italian patients with Lafora disease. Epilepsia 47(3):640–643
10. Baykan B, Striano P, Gianotti S et al (2005) Late-onset and slow-progressing Lafora disease in four siblings with EPM2B mutation. Epilepsia 46(10):1695–1697
11. Ganesh S, Delgado-Escueta AV, Suzuki T et al (2002) Genotype-phenotype correlations for EPM2A mutations in Lafora’s progressive myoclonic epilepsy: exon 1 mutations associated with an early-onset cognitive deficit subphenotype. Hum Mol Genet 11(11):1263–1271
12. Amadori E, Scala M, Cereda GS et al (2020) Targeted re-sequencing for early diagnosis of genetic causes of childhood epilepsy: the Italian experience from the “beyond epilepsy” project. Ital J Pediatr 46(1):92
13. Fishman GA, Jacobson SG, Alexander KR et al (2005) Outcome measures and their application in clinical trials for retinal degenerative diseases: outline, review, and perspective. Retina 25(6):772–777
14. Hologopian K, Seiple W, Greenstein VC, Hood DC, Carr RE (2001) Local cone and rod system function in patients with retinitis pigmentosa. Invest Ophthalmol Vis Sci 42(3):779–788
15. Kretschmann U, Seelig MW, Ruetkert K, Usui T, Apfelstedt-Sylla E, Zrenner E (1998) Multifocal electroretinography in patients with Stargardt’s macular dystrophy. Br J Ophthalmol 82(3):267–275
16. Ashworth JL, Biswas S, Wraith E, Lloyd IC (2006) The ocular features of the mucopolysaccharidoses. Eye (Lond) 20(5):553–563
17. Francis JH, Abramson DH, Gobin YP et al (2014) Electroretinogram monitoring of dose-dependent toxicity after ophthalmic artery chemoembolization in patients with retinoblastoma. Ophthal Plast Reconstr Surg 30(6):491–495
18. Dettoraki M, Moschos MM (2016) The role of multifocal electroretinography in the assessment of drug-induced retinopathy: a review of the literature. Ophthalmic Res 56(4):169–177
19. Vincent A, Macri A, Tumber A et al (2018) Ocular phenotype and electoretinogram abnormalities in Lafora disease: a “window to the brain.” Neurology 91(3):137–139
20. O’Donnell BF, Blekher TM, Weaver M et al (2008) Visual perception in prediagnostic and early stage Huntington’s disease. J Int Neuropsychol Soc 14(3):446–453
21. Korczyn AD, Ben-Tovim N (1978) Electoretinographic responses in Lafora disease. Electroencephalogr Clin Neurophysiol 45(6):785–788
22. Heitkotter H, Linderman RE, Cava JA, Woertz EN, Mastey RR, Summerfelt P, Chiu TY, Rosen RB, Patterson EJ, Vincent A, Carroll J, Minassian BA (2021) Retinal alterations in patients with Lafora disease. Am J Ophthalmol Case Rep 23:101146. https://doi.org/10.1016/j.ajoc.2021.101146

© Springer